News

UK Biotech & Life Sciences News

Follow the latest UK life sciences company news, including biotech funding rounds, pharma partnerships, product launches, clinical updates, infrastructure projects and commercial announcements.

Latest updates
Showing 61–72 of 243 stories

Catalent Appoints Wetteny Joseph to Lead Pharma and Consumer Health

Catalent appointed Wetteny Joseph as Group President, Pharma and Consumer Health, effective 2 November 2026. He succeeds Aris Gennadios and will lead a business covering oral drug delivery and manufacturing, alongside consumer health solutions. Joseph rejoins Catalent from Zoetis, where he was Executive Vice President and Chief Financial Officer, and previously held senior finance and clinical supply leadership positions at Catalent.

Qureight Publishes Viewpoint on CT Fibrosis Biomarkers in Trials

Qureight has announced a peer-reviewed Viewpoint in the European Respiratory Journal proposing that fibrosis extent measured using quantitative high-resolution CT could complement lung-function testing in antifibrotic trials. The authors argue that imaging may capture structural disease changes more directly than forced vital capacity alone. They also state that further trial-level evidence is needed before fibrosis extent could qualify as a regulatory surrogate endpoint.

Iksuda Reports Preliminary Phase 1 IKS014 Data Ahead of SABCS

Iksuda Therapeutics reported preliminary Phase 1 findings for IKS014, its HER2-directed antibody-drug conjugate, ahead of a December scientific presentation. Among 105 treated patients, 16 experienced Grade 3 treatment-related adverse events. In a subgroup of ten response-evaluable breast cancer patients previously treated with trastuzumab deruxtecan, five had confirmed or unconfirmed partial responses. The findings are preliminary and do not establish efficacy in a larger patient population.

Illumina Selected for Singapore's 450,000-Person Genomics Study

Illumina has been selected to provide whole-genome sequencing services for SG-INSIGHT, part of Phase III of Singapore's National Precision Medicine programme. The cohort aims to include around 450,000 residents and link genomic and health information to inform preventive healthcare. Illumina will perform sequencing at its Singapore facility, while a separate consortium led by Lucence has also been appointed for the programme.

EnteroBiotix Appoints Former GSK Medical Chief Murray Stewart to Board

EnteroBiotix announced the appointment of Dr Murray Stewart to its board of directors on 2 November 2026. Stewart previously served as Chief Medical Officer at GSK and Rhythm Pharmaceuticals and held research and development leadership roles at Novelion Therapeutics. EnteroBiotix said his clinical and regulatory experience will support development of its microbiome therapeutics, including the ongoing Phase 2b RISE study in irritable bowel syndrome with constipation.

Tiziana Reports Phase 2a INFORM-MS Trial Meets Primary Endpoints

Tiziana Life Sciences reported that its 48-patient Phase 2a INFORM-MS trial of intranasal foralumab in non-active secondary progressive multiple sclerosis met both primary endpoints covering PET-measured microglial activation and safety. The 50 μg group showed a statistically significant reduction in the imaging marker versus placebo after 12 weeks. The company also reported improvements in fatigue scores, although the trial was not powered to establish definitive clinical efficacy.

Inovia Bio Launches InovaMine Biostatistics and Reporting Software

Inovia Bio has made InovaMine available as a standalone software product for biostatistics and clinical-data reporting. The platform takes datasets and statistical analysis plans, generates tables, listings and figures, and links reported results back to source records for traceability. According to the company, statistical outputs are reviewed and signed off by a statistician before release.

Azenta Acquires SynPlexity and Licenses Elegen DNA Technology

Azenta has acquired SynPlexity and signed an exclusive licensing agreement with Elegen to expand the gene synthesis capabilities of its GENEWIZ business. SynPlexity adds pooled gene assembly technology for high-throughput variant libraries, while Elegen's cell-free DNA manufacturing platform is intended to support sequence-verified constructs and faster production. Azenta plans to integrate both technologies into existing GENEWIZ discovery and gene-to-antibody workflows.

Funding & Grants30 Oct 2026

VasoDynamics Receives Innovate UK Grant Offer for Bradford Research

VasoDynamics has received an Innovate UK Accelerate Knowledge Transfer grant offer to support a collaboration with the University of Bradford. The project will generate additional safety data in mouse models for the company's topical formulations, which are being developed to reduce adverse effects of anticancer treatments. The offer supports planned preclinical work; the announcement does not state that grant funding has been paid or the project completed.